Immunohistochemical Expression of Programmed Death Ligand-1 and CD-8 in Glioblastoma

Abstract

Glioblastoma is the most common and most aggressive primary malignant brain tumor in adults. It is characterized by poor prognosis. Glioblastoma has been recognized as an immunosuppressive neoplasm. Immune evasion is described in Glioblastoma via Programmed death ligand 1 (PD-L1)/ Programmed death receptor- 1 (PD-1) interaction. A novel class of immune modulatory antineoplastic agents, called “immune checkpoint inhibitors”, showed impressive activity with high response rates and durable tumor remissions in several cancer types using PD-L1/PD1 blockade treatment strategies. Tumor infiltrating lymphocytes are considered as a component of the adaptive antitumor host response, and transfer of TILs was proved to facilitate regression in some tumors such as in metastatic melanoma. The aim of this study is to determine the immunohistochemical expression of Programmed Death Ligand-1 and CD-8 in various cases of Glioblastoma and to correlate their expression to various clinicopathologic parameters aiming to highlight their role as promising markers for Glioblastoma.